B Group Inc. Acquires Shares of 15,000 Apogee Therapeutics, Inc. (NASDAQ:APGE)

B Group Inc. acquired a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 15,000 shares of the company's stock, valued at approximately $680,000. Apogee Therapeutics accounts for approximately 0.4% of B Group Inc.'s investment portfolio, making the stock its 14th biggest position.

Several other institutional investors have also recently added to or reduced their stakes in APGE. Barclays PLC grew its position in shares of Apogee Therapeutics by 369.2% during the 3rd quarter. Barclays PLC now owns 365,046 shares of the company's stock valued at $21,443,000 after buying an additional 287,243 shares during the last quarter. Affinity Asset Advisors LLC raised its position in shares of Apogee Therapeutics by 40.3% during the 4th quarter. Affinity Asset Advisors LLC now owns 931,728 shares of the company's stock worth $42,207,000 after purchasing an additional 267,530 shares during the period. Capital World Investors acquired a new position in Apogee Therapeutics during the 4th quarter valued at approximately $9,291,000. Alliancebernstein L.P. increased its position in Apogee Therapeutics by 13.5% in the fourth quarter. Alliancebernstein L.P. now owns 1,355,185 shares of the company's stock worth $61,390,000 after buying an additional 160,822 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Apogee Therapeutics by 11.2% during the third quarter. Geode Capital Management LLC now owns 823,839 shares of the company's stock valued at $48,401,000 after acquiring an additional 82,978 shares during the period. Institutional investors own 79.04% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Citigroup began coverage on shares of Apogee Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $95.00 price objective on the stock. Guggenheim reiterated a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Finally, Wedbush restated an "outperform" rating and issued a $90.00 target price on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $92.17.

Apogee Therapeutics Price Performance

Shares of Apogee Therapeutics stock traded down $0.20 on Friday, hitting $36.85. The company had a trading volume of 578,730 shares, compared to its average volume of 512,343. Apogee Therapeutics, Inc. has a 52 week low of $26.20 and a 52 week high of $63.50. The company has a market cap of $1.66 billion, a PE ratio of -15.23 and a beta of 1.72. The business has a 50-day simple moving average of $35.15 and a 200-day simple moving average of $42.81.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.25). On average, equities research analysts predict that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 10,000 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total value of $301,500.00. Following the transaction, the chief executive officer now owns 1,292,987 shares in the company, valued at approximately $38,983,558.05. The trade was a 0.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Carl Dambkowski sold 3,520 shares of the company's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $40.69, for a total value of $143,228.80. Following the completion of the transaction, the insider now directly owns 252,623 shares in the company, valued at $10,279,229.87. This represents a 1.37 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,970 shares of company stock worth $1,241,701. 36.10% of the stock is owned by corporate insiders.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.